Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Innosolid** is a prescription, semi-solid enteral nutrition formulation developed by EN Otsuka Pharmaceutical for nutritional support in patients who cannot maintain adequate oral intake, including patients receiving gastrostomy tube feeding. Originally developed under the code **EN-P09**, it provides balanced macronutrients, vitamins, trace elements, L-carnitine, and inulin; its formulation was designed so that approximately 900 kcal can substantially meet recommended daily vitamin and trace-element intakes for patients with relatively low maintenance-energy requirements. It is administered into the stomach through a gastrostomy tube and was approved in Japan as Innosolid Combination Semi-solid for Enteral Use. ([pmda.go.jp](https://www.pmda.go.jp/drugs/2024/P20240919002/130589000_30600AMX00242000_A100_1.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Innosolid.